Clinical heterogeneity reflects biologic diversity in chronic lymphocytic leukemia

As the incidence of B cell chronic lymphocytic leukemia increases in an aging population, it becomes more important to re-evaluate our understanding of the disease process and current therapy. Previous treatment strategies have been, for the most part, unsuccessful in prolonging survival and thus ne...

Full description

Saved in:
Bibliographic Details
Published inCritical reviews in oncology/hematology Vol. 20; no. 1; pp. 141 - 164
Main Authors Moore, Jonni S., Friedman, David F., Silberstein, Leslie E., Besa, Emmanuel C., Nowell, Peter C.
Format Journal Article
LanguageEnglish
Published Shannon Elsevier Ireland Ltd 01.08.1995
Elsevier Science
Subjects
Biological and medical sciences
Hematologic and hematopoietic diseases
Humans
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell - genetics
Leukemia, Lymphocytic, Chronic, B-Cell - pathology
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical sciences
Chromosomal aberration
Human
Immunoglobulins
Cytokine
Malignant hemopathy
B-Lymphocyte
Carcinogenesis
Chronic
Chronic lymphocytic leukemia
Phenotype
Regulation(control)
Treatment
Gene
Lymphoproliferative syndrome
Tumor progression
Online AccessGet full text

Cover

More Information
Summary:As the incidence of B cell chronic lymphocytic leukemia increases in an aging population, it becomes more important to re-evaluate our understanding of the disease process and current therapy. Previous treatment strategies have been, for the most part, unsuccessful in prolonging survival and thus new approaches are needed. More intense cellular and molecular research on the biologic diversity of this neoplasm will further our understanding of the causes of clinical heterogeneity and refine our ability to predict progression. New approaches, based on alterations of neoplastic cell growth by cytokines or chemotherapeutic agents, may enable clinicians to ‘customize’ individual treatments based on the stages of CLL B cell differentiation and our understanding of factors involved in the regulation of apoptosis and proliferation at those stages. Taken together, these efforts should ultimately yield much new information that will lead to reduced morbidity and mortality in BCLL, the most common form of human leukemia.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1040-8428
1879-0461
DOI:10.1016/1040-8428(94)00150-R